RBC Capital upgraded MannKind (MNKD) to Outperform from Sector Perform with a price target of $10, up from $7.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- MannKind announces exchange of convertible notes for stock, cash
- MannKind reports six-month results from Phase 3 INHALE-1 trial
- MannKind, Cipla: CDSCO in India approves Afrezza Inhalation Powder in India
- Leerink healthcare analysts hold an analyst/industry conference call
- MannKind price target raised to $7 from $5 at RBC Capital